IP Library › Granted Patent US 12,364,768
Granted Patent B2
US 12,364,768 · App. 17/493,266 · Granted Jul 22, 2025

Nectin-4 antibody conjugates and uses thereof

Inventors: Peter R. Baum (Seattle, WA); Robert Dubose (Seattle, WA); Valerie Odegard (Seattle, WA); Brenda Stevens (Seattle, WA); Philip Tan (Seattle, WA)
Assignee: ARARIS BIOTECH AG
A61K47/6803A61K31/55A61K47/65A61K47/6849A61P35/00C07K16/2803C07K16/2818C07K16/2827A61K2039/505C07K2317/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,364,768
App. No.
17/493,266
Granted
Jul 22, 2025
Kind
B2
Abstract

The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.

Claims (31)

1. An isolated monoclonal antibody, or an antigen-binding fragment thereof, that specifically binds to Nectin-4, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL),

(1) wherein the VH comprises a CDR1 (VH-CDR1) comprising the amino acid sequence of SEQ ID NO:1, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:2, a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:3; and the VL comprises a CDR1 (VL-CDR1) comprising the amino acid sequence selected from any one of SEQ ID NOS: 4-6, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:8;

(2) wherein the VH comprises a CDR1 (VH-CDR1) comprising the amino acid sequence of SEQ ID NO:33, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO: 34, a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:35; and the VL comprises a CDR1 (VL-CDR1) comprising the amino acid sequence of SEQ ID NO:36, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:37, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:38;

(3) wherein the VH comprises a CDR1 (VH-CDR1) comprising the amino acid sequence of SEQ ID NO:39, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO: 40, a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:41; and the VL comprises a CDR1 (VL-CDR1) comprising the amino acid sequence of SEQ ID NO:42, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:43, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:44;

(4) wherein the VH comprises a CDR1 (VH-CDR1) comprising the amino acid sequence of SEQ ID NO:45, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO: 46, a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:47; and the VL comprises a CDR1 (VL-CDR1) comprising the amino acid sequence of SEQ ID NO:48, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:49, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:50;

(5) wherein the VH comprises a CDR1 (VH-CDR1) comprising the amino acid sequence of SEQ ID NO:51, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO: 52, a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:53; and the VL comprises a CDR1 (VL-CDR1) comprising the amino acid sequence of SEQ ID NO:54, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:55, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:56; or

(6) wherein the VH comprises a CDR1 (VH-CDR1) comprising the amino acid sequence of SEQ ID NO:57, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO: 58, a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:59; and the VL comprises a CDR1 (VL-CDR1) comprising the amino acid sequence of SEQ ID NO:60, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:61, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:62.

2. The antibody of claim 1 , wherein the antibody is a humanized antibody.

3. The antibody of claim 1 , wherein the antibody comprises:

(a) a VH comprising an amino acid sequence that has at least 90% identity with the amino acid sequence of SEQ ID NO:10, and a VL comprising an amino acid sequence that has at least 90% identity with the amino acid sequence selected from any one of SEQ ID NOS: 12-17; or

(b) a VH comprising the amino acid sequence of SEQ ID NO:10, and a VL comprising the amino acid sequence selected from any one of SEQ ID NOS: 12-17.

4. The antibody of claim 1 , wherein the VL-CDR1 comprises the amino acid sequence of SEQ ID NO:5.

5. The antibody of claim 4 , wherein the VL comprises the amino acid sequence of SEQ ID NO:14.

6. The antibody of claim 1 , wherein the VL-CDR1 comprises the amino acid sequence of SEQ ID NO:4.

7. The antibody of claim 6 , wherein the VL comprises the amino acid sequence of SEQ ID NO: 13.

8. The antibody of claim 1 , wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO:10.

9. The antibody of claim 1 , wherein the antibody comprises a human IgG1, human IgG2, human IgG3, or human IgG4 constant region.

10. The antibody of claim 1 , wherein the antibody comprises:

(a) a heavy chain comprising an amino acid sequence that is at least 90% identity with the amino acid sequence of SEQ ID NO:24, and a light chain comprising an amino acid sequence that has at least 90% identity with the amino acid sequence selected from any one of SEQ ID NOS: 26-31; or

(b) a heavy chain comprising an amino acid sequence of SEQ ID NO:24, and a light chain comprising the amino acid sequence selected from any one of SEQ ID NOS: 26-31.

11. The antibody of claim 10 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:24, and a light chain comprising the amino acid sequence of SEQ ID NO:28.

12. The antibody of claim 10 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:24, and a light chain comprising the amino acid sequence of SEQ ID NO:27.

13. A conjugate comprising the antibody of claim 1 and a small molecule drug.

14. The conjugate of claim 13 , wherein the small molecule drug is a TLR8 agonist.

15. A pharmaceutical composition comprising an antibody of claim 1 and a pharmaceutically acceptable carrier.

16. An isolated nucleic acid that encodes the antibody of claim 1 .

17. A vector comprising the nucleic acid of claim 16 .

18. An isolated host cell comprising the nucleic acid of claim 16 .

19. An isolated host cell that expresses the antibody of claim 1 .

20. A method of producing an antibody that binds nectin-4, comprising culturing the host cell of claim 19 under conditions suitable for expressing the antibody.

21. The method of claim 20 , further comprising isolating the antibody.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2023
From: ARS PHARMACEUTICALS, INC.
To: ARARIS BIOTECH AG
Reel/Frame 063397/0878 →
CHANGE OF NAME Recorded Mar 10, 2023
From: SILVERBACK THERAPEUTICS, INC.
To: ARS PHARMACEUTICALS, INC.
Reel/Frame 063038/0951 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2023
From: BAUM, PETER R.; DUBOSE, ROBERT; ODEGARD, VALERIE; STEVENS, BRENDA; TAN, PHILIP
To: SILVERBACK THERAPEUTICS, INC.
Reel/Frame 062895/0873 →
Continuity (5)
Continuation 17180110 · Feb 19, 2021
Provisional Application 63092714 · Oct 16, 2020
Provisional Application 63047124 · Jul 1, 2020
Provisional Application 62979755 · Feb 21, 2020
Related Publication 20220105196A1 · Apr 7, 2022
References Cited (345)
US 5846514A · Foster et al. · 1998 [cited by applicant]
US 6043238A · Cooper et al. · 2000 [cited by applicant]
US 6334997B1 · Foster et al. · 2002 [cited by applicant]
US 6942972B2 · Farooqui et al. · 2005 [cited by applicant]
US 7387271B2 · Noelle et al. · 2008 [cited by applicant]
US 7923560B2 · Wightman et al. · 2011 [cited by applicant]
US 8236318B2 · Keler et al. · 2012 [cited by applicant]
US 8357374B2 · Carson et al. · 2013 [cited by applicant]
US 8729088B2 · Carson et al. · 2014 [cited by applicant]
US 8951528B2 · Stoermer et al. · 2015 [cited by applicant]
US 9556167B2 · Spiegel et al. · 2017 [cited by applicant]
US 9655964B2 · Perez et al. · 2017 [cited by applicant]
US 9670272B2 · Nitsch et al. · 2017 [cited by applicant]
US 9670276B2 · Lacy et al. · 2017 [cited by applicant]
US 9676845B2 · Imhof-Jung et al. · 2017 [cited by applicant]
US 9695233B2 · Duerr et al. · 2017 [cited by applicant]
US 9827329B2 · Li · 2017 [cited by applicant]
US 9856319B2 · Ghayur et al. · 2018 [cited by applicant]
US 9878052B2 · Li · 2018 [cited by applicant]
US 9914776B2 · Ast et al. · 2018 [cited by applicant]
US 9926379B2 · Bruenker et al. · 2018 [cited by applicant]
US 9943416B2 · Arramon et al. · 2018 [cited by applicant]
US 9944573B2 · Radaelli et al. · 2018 [cited by applicant]
US 9956091B2 · de Villiers et al. · 2018 [cited by applicant]
US 10035853B2 · Arathoon et al. · 2018 [cited by applicant]
US 10233184B2 · Gao et al. · 2019 [cited by applicant]
US 10239862B2 · Coburn et al. · 2019 [cited by applicant]
US 10253003B2 · Last et al. · 2019 [cited by applicant]
US 10428045B2 · Coburn et al. · 2019 [cited by applicant]
US 10442790B2 · Coburn et al. · 2019 [cited by applicant]
US 10472420B2 · Stoermer et al. · 2019 [cited by applicant]
US 10519131B2 · Coburn et al. · 2019 [cited by applicant]
US 11179473B2 · Baum et al. · 2021 [cited by applicant]
US 20040091491A1 · Kedl et al. · 2004 [cited by applicant]
US 20040141950A1 · Noelle et al. · 2004 [cited by applicant]
US 20040213797A1 · Bodmer et al. · 2004 [cited by applicant]
US 20060135459A1 · Epstein et al. · 2006 [cited by applicant]
US 20060142202A1 · Alkan et al. · 2006 [cited by applicant]
US 20070092940A1 · Eigenbrot et al. · 2007 [cited by applicant]
US 20080234251A1 · Doherty et al. · 2008 [cited by applicant]
US 20080306050A1 · Doherty et al. · 2008 [cited by applicant]
US 20090004194A1 · Kedl · 2009 [cited by applicant]
US 20090035323A1 · Stoermer et al. · 2009 [cited by applicant]
US 20090047249A1 · Graupe et al. · 2009 [cited by applicant]
US 20090074711A1 · Glennie · 2009 [cited by applicant]
US 20090087440A1 · Vicari et al. · 2009 [cited by applicant]
US 20090123467A1 · Bedi et al. · 2009 [cited by applicant]
US 20100029585A1 · Howbert et al. · 2010 [cited by applicant]
US 20100143301A1 · Desai et al. · 2010 [cited by applicant]
US 20100291109A1 · Kedl · 2010 [cited by applicant]
US 20110033383A1 · Spencer et al. · 2011 [cited by applicant]
US 20110092485A1 · Howbert et al. · 2011 [cited by applicant]
US 20110098248A1 · Halcomb et al. · 2011 [cited by applicant]
US 20110117013A1 · Mack et al. · 2011 [cited by applicant]
US 20110118235A1 · Howbert et al. · 2011 [cited by applicant]
US 20110214206A1 · La Rosa et al. · 2011 [cited by applicant]
US 20110274653A1 · Banchereau et al. · 2011 [cited by applicant]
US 20110287038A1 · Slawin et al. · 2011 [cited by applicant]
US 20110301056A1 · Nakamura et al. · 2011 [cited by applicant]
US 20120039916A1 · Zurawski et al. · 2012 [cited by applicant]
US 20120078028A1 · Satpayev et al. · 2012 [cited by applicant]
US 20120082658A1 · Hershberg · 2012 [cited by applicant]
US 20120151504A1 · Schwalbe et al. · 2012 [cited by applicant]
US 20120219615A1 · Hershberg et al. · 2012 [cited by applicant]
US 20120231023A1 · Zurawski et al. · 2012 [cited by applicant]
US 20120263732A1 · Gladue et al. · 2012 [cited by applicant]
US 20130129729A1 · Kischel et al. · 2013 [cited by applicant]
US 20130171152A1 · Spriggs et al. · 2013 [cited by applicant]
US 20130251673A1 · Hartman et al. · 2013 [cited by applicant]
US 20130295091A1 · Esslinger et al. · 2013 [cited by applicant]
US 20130295110A1 · Binder et al. · 2013 [cited by applicant]
US 20130309256A1 · Lyon et al. · 2013 [cited by applicant]
US 20140045849A1 · McGowan et al. · 2014 [cited by applicant]
US 20140066432A1 · Howbert et al. · 2014 [cited by applicant]
US 20140073642A1 · McGowan et al. · 2014 [cited by applicant]
US 20140088085A1 · Burgess et al. · 2014 [cited by applicant]
US 20140154252A1 · Thompson et al. · 2014 [cited by applicant]
US 20140187501A1 · Bilodeau et al. · 2014 [cited by applicant]
US 20140205653A1 · Dubensky, Jr. et al. · 2014 [cited by applicant]
US 20140275167A1 · Hartman · 2014 [cited by applicant]
US 20140341976A1 · Dubensky, Jr. et al. · 2014 [cited by applicant]
US 20140350031A1 · McGowan et al. · 2014 [cited by applicant]
US 20150044279A1 · Miller et al. · 2015 [cited by applicant]
US 20150141625A1 · Stoermer et al. · 2015 [cited by applicant]
US 20150174268A1 · Li · 2015 [cited by applicant]
US 20150299194A1 · Hoves et al. · 2015 [cited by applicant]
US 20160015803A1 · Kedl · 2016 [cited by applicant]
US 20160108045A1 · Andres et al. · 2016 [cited by applicant]
US 20160129095A1 · Noelle et al. · 2016 [cited by applicant]
US 20160130358A1 · Bhakta et al. · 2016 [cited by applicant]
US 20160159904A1 · Yamazaki et al. · 2016 [cited by applicant]
US 20160168164A1 · McGowan et al. · 2016 [cited by applicant]
US 20160199510A1 · McDonald et al. · 2016 [cited by applicant]
US 20160250223A1 · Smith et al. · 2016 [cited by applicant]
US 20160257653A1 · Hoves et al. · 2016 [cited by applicant]
US 20160289341A1 · Wu · 2016 [cited by applicant]
US 20160289343A1 · Wu · 2016 [cited by applicant]
US 20160375148A1 · Li · 2016 [cited by applicant]
US 20170014423A1 · Hoves et al. · 2017 [cited by applicant]
US 20170028079A1 · Li · 2017 [cited by applicant]
US 20170071944A1 · Geleziunas et al. · 2017 [cited by applicant]
US 20170088613A1 · Grogan et al. · 2017 [cited by applicant]
US 20170121421A1 · Cortez et al. · 2017 [cited by applicant]
US 20170145087A1 · Krause et al. · 2017 [cited by applicant]
US 20170145116A1 · Regula et al. · 2017 [cited by applicant]
US 20170151329A1 · Krause et al. · 2017 [cited by applicant]
US 20170158758A1 · Ramasubramanyan et al. · 2017 [cited by applicant]
US 20170158759A1 · Krause et al. · 2017 [cited by applicant]
US 20170158772A1 · Thompson et al. · 2017 [cited by applicant]
US 20170174786A1 · Bacac et al. · 2017 [cited by applicant]
US 20170190783A1 · Bacac et al. · 2017 [cited by applicant]
US 20170253670A1 · Klein et al. · 2017 [cited by applicant]
US 20170298139A1 · Thompson et al. · 2017 [cited by applicant]
US 20170342169A1 · Akamatsu et al. · 2017 [cited by applicant]
US 20170349669A1 · Imhof-Jung et al. · 2017 [cited by applicant]
US 20180065938A1 · Chin et al. · 2018 [cited by applicant]
US 20180079805A1 · Imhof-Jung et al. · 2018 [cited by applicant]
US 20180086755A1 · Chin et al. · 2018 [cited by applicant]
US 20180112004A1 · Liu et al. · 2018 [cited by applicant]
US 20180258048A1 · Coburn et al. · 2018 [cited by applicant]
US 20180263985A1 · Geleziunas et al. · 2018 [cited by applicant]
US 20190015516A1 · Jackson et al. · 2019 [cited by applicant]
US 20190016808A1 · Li · 2019 [cited by applicant]
US 20190055247A1 · He et al. · 2019 [cited by applicant]
US 20190076547A1 · Alonso et al. · 2019 [cited by applicant]
US 20190107537A1 · Chaudhary · 2019 [cited by applicant]
US 20190112380A1 · Chaudhary · 2019 [cited by applicant]
US 20190153471A1 · Paul et al. · 2019 [cited by applicant]
US 20190194713A1 · Mandell et al. · 2019 [cited by applicant]
US 20190336615A1 · Thompson et al. · 2019 [cited by applicant]
US 20200031798A1 · Coburn et al. · 2020 [cited by applicant]
US 20200101142A1 · Suri et al. · 2020 [cited by applicant]
US 20200113912A1 · Odegard et al. · 2020 [cited by applicant]
US 20200199242A1 · Thompson · 2020 [cited by applicant]
US 20200231670A1 · Morrison et al. · 2020 [cited by applicant]
US 20210077632A1 · Smith et al. · 2021 [cited by applicant]
US 20210115109A1 · Thompson et al. · 2021 [cited by applicant]
US 20210139477A1 · Smith et al. · 2021 [cited by applicant]
US 20210139604A1 · Thompson et al. · 2021 [cited by applicant]
US 20210154317A1 · Thompson et al. · 2021 [cited by applicant]
US 20210275683A1 · Baum et al. · 2021 [cited by applicant]
CA 3085424A1 · 2019 [cited by applicant]
CN 102753542A · 2012 [cited by applicant]
CN 102781933A · 2012 [cited by applicant]
CN 103562186A · 2014 [cited by applicant]
EP 2436696A1 · 2012 [cited by applicant]
EP 2604625A1 · 2013 [cited by applicant]
EP 2787005A1 · 2014 [cited by applicant]
EP 2663580B1 · 2016 [cited by applicant]
EP 2817338B1 · 2017 [cited by applicant]
EP 2747781B1 · 2017 [cited by applicant]
EP 3589654A1 · 2020 [cited by applicant]
EP 3603671A2 · 2020 [cited by applicant]
EP 3635013A1 · 2020 [cited by applicant]
WO 0076505A1 · 2000 [cited by applicant]
WO WO2000076505A1 · 2000 [cited by applicant]
WO WO2020190762A1 · 2002 [cited by applicant]
WO 03094836A2 · 2003 [cited by applicant]
WO WO2003094836A2 · 2003 [cited by applicant]
WO WO2004091658A1 · 2004 [cited by applicant]
WO WO2005065678A1 · 2005 [cited by applicant]
WO WO2006052900A2 · 2006 [cited by applicant]
WO WO2007005874A2 · 2007 [cited by applicant]
WO WO2007024612A2 · 2007 [cited by applicant]
WO WO2009018500A1 · 2009 [cited by applicant]
WO WO2009084659A1 · 2009 [cited by applicant]
WO WO2011012637A2 · 2011 [cited by applicant]
WO WO2011017070A1 · 2011 [cited by applicant]
WO WO2011022508A2 · 2011 [cited by applicant]
WO WO2011022509A2 · 2011 [cited by applicant]
WO WO2011090088A1 · 2011 [cited by applicant]
WO WO2011104381A2 · 2011 [cited by applicant]
WO WO2011147921A1 · 2011 [cited by applicant]
WO WO2012021834A1 · 2012 [cited by applicant]
WO WO2012078688A2 · 2012 [cited by applicant]
WO WO2012095412A1 · 2012 [cited by applicant]
WO WO2012097173A2 · 2012 [cited by applicant]
WO WO2012097177A2 · 2012 [cited by applicant]
WO WO2012122396A1 · 2012 [cited by applicant]
WO WO2012151199A1 · 2012 [cited by applicant]
WO WO2013093465A2 · 2013 [cited by applicant]
WO WO2013096835A1 · 2013 [cited by applicant]
WO WO2013173687A1 · 2013 [cited by applicant]
WO WO2014012479A1 · 2014 [cited by applicant]
WO WO2014023813A1 · 2014 [cited by applicant]
WO WO2014052828A1 · 2014 [cited by applicant]
WO WO2014056953A1 · 2014 [cited by applicant]
WO WO2014076221A1 · 2014 [cited by applicant]
WO WO2014122144A1 · 2014 [cited by applicant]
WO WO2014124258 · 2014 [cited by examiner]
WO WO2014128189A1 · 2014 [cited by applicant]
WO WO2014172532A2 · 2014 [cited by applicant]
WO WO2015103987A1 · 2015 [cited by applicant]
WO WO2015103989A1 · 2015 [cited by applicant]
WO WO2015103990A1 · 2015 [cited by applicant]
WO WO2015108595A1 · 2015 [cited by applicant]
WO WO2015112749A2 · 2015 [cited by applicant]
WO WO2015162293A1 · 2015 [cited by applicant]
WO WO2016004875A1 · 2016 [cited by applicant]
WO WO2016004876A1 · 2016 [cited by applicant]
WO WO2016016299A1 · 2016 [cited by applicant]
WO WO2016036678A1 · 2016 [cited by applicant]
WO WO2016040856A2 · 2016 [cited by applicant]
WO WO2016064899A1 · 2016 [cited by applicant]
WO WO2016075670A1 · 2016 [cited by applicant]
WO WO2016096174A1 · 2016 [cited by applicant]
WO WO2016096778A1 · 2016 [cited by applicant]
WO WO2016100302A2 · 2016 [cited by applicant]
WO WO2016120305A1 · 2016 [cited by applicant]
WO WO2016142250A1 · 2016 [cited by applicant]
WO WO2017023779A1 · 2017 [cited by applicant]
WO WO2017024296A1 · 2017 [cited by applicant]
WO WO2017027645A1 · 2017 [cited by applicant]
WO WO2017027646A1 · 2017 [cited by applicant]
WO WO2017046112A1 · 2017 [cited by applicant]
WO WO2017072662A1 · 2017 [cited by applicant]
WO WO2017091745A1 · 2017 [cited by applicant]
WO WO2017093404A1 · 2017 [cited by applicant]
WO WO2017093406A1 · 2017 [cited by applicant]
WO WO2017100305A2 · 2017 [cited by applicant]
WO WO2017117269A1 · 2017 [cited by applicant]
WO WO2017118405A1 · 2017 [cited by applicant]
WO WO2017123657A1 · 2017 [cited by applicant]
WO WO2017123669A1 · 2017 [cited by applicant]
WO WO2017139623A1 · 2017 [cited by applicant]
WO WO2017147368A1 · 2017 [cited by applicant]
WO WO2017161349A1 · 2017 [cited by applicant]
WO WO2017190669A1 · 2017 [cited by applicant]
WO WO2017202703A1 · 2017 [cited by applicant]
WO WO2017202704A1 · 2017 [cited by applicant]
WO WO2017216054A1 · 2017 [cited by applicant]
WO WO2018002358A1 · 2018 [cited by applicant]
WO WO2018009466A1 · 2018 [cited by applicant]
WO WO2018009916A1 · 2018 [cited by applicant]
WO WO2018045204A1 · 2018 [cited by applicant]
WO WO2018060323A1 · 2018 [cited by applicant]
WO WO2018065360A1 · 2018 [cited by applicant]
WO WO2018098203A1 · 2018 [cited by applicant]
WO WO2018100558A2 · 2018 [cited by applicant]
WO WO2018102795A2 · 2018 [cited by applicant]
WO WO2018112108A1 · 2018 [cited by applicant]
WO WO2018119118A1 · 2018 [cited by applicant]
WO WO2018136412A2 · 2018 [cited by applicant]
WO WO2018138685A2 · 2018 [cited by applicant]
WO WO2018140831A2 · 2018 [cited by applicant]
WO WO2018144955A1 · 2018 [cited by applicant]
WO WO2018152453A1 · 2018 [cited by applicant]
WO WO2018156625A1 · 2018 [cited by applicant]
WO WO2018158398A1 · 2018 [cited by applicant]
WO WO2018170179A1 · 2018 [cited by applicant]
WO WO2018191746A1 · 2018 [cited by applicant]
WO WO2018198091A1 · 2018 [cited by applicant]
WO WO2018226578A1 · 2018 [cited by applicant]
WO WO2018227018A1 · 2018 [cited by applicant]
WO WO2018227023A1 · 2018 [cited by applicant]
WO WO2019067805A1 · 2019 [cited by applicant]
WO WO2019084060A1 · 2019 [cited by applicant]
WO WO2019099412A1 · 2019 [cited by applicant]
WO WO2019118884A1 · 2019 [cited by applicant]
WO WO2019215728A1 · 2019 [cited by applicant]
WO WO2019241315A1 · 2019 [cited by applicant]
WO WO2020047187A1 · 2020 [cited by applicant]
WO WO2020056008A1 · 2020 [cited by applicant]
WO WO2020056192A1 · 2020 [cited by applicant]
WO WO2020056194A1 · 2020 [cited by applicant]
WO WO2020056198A2 · 2020 [cited by applicant]
WO WO2020150702A1 · 2020 [cited by applicant]
WO WO2020190725A1 · 2020 [cited by applicant]
WO WO2020190731A1 · 2020 [cited by applicant]
WO WO2020190734A1 · 2020 [cited by applicant]
WO WO2020190760A1 · 2020 [cited by applicant]
WO WO2020252254A1 · 2020 [cited by applicant]
WO WO2020252294A1 · 2020 [cited by applicant]
WO WO2020257407A1 · 2020 [cited by applicant]
WO WO2021007428A2 · 2021 [cited by applicant]
WO WO2021030665A1 · 2021 [cited by applicant]
WO WO2021067644A1 · 2021 [cited by applicant]
U.S. Appl. No. 17/180,110 2021/0275683 U.S. Pat. No. 11,179,473, filed Feb. 19, 2021 Sep. 9, 2012 Nov. 23, 2021, Peter R. Baum, Nectin-4 Antibody Conjugates and Uses Thereof. [cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” [cited by applicant]
Alves, “Antibody conjugation and formulation,” [cited by applicant]
Anonymous “Silverback Therapeutics,” URL: https://www.sec.gov/Archives/edgar/data/1671858/000119312520290236/d67046ds1.htm, download date Aug. 19, 2021. (279 pages). [cited by applicant]
Berge et al., “Pharmaceutical Salts,” [cited by applicant]
Bolt Biotherapeutics: “A First-in-human Study Using BDC-1001 in Advanced HER2-Expressing Solid Tumors,” URL: https://clinicaltrials.gov/ct2/show/record/NCT04278144?term=NCT04278144&draw=1&rank=1, download date Jan. 12, … [cited by applicant]
Capon et al., “Designing CD4 immunoadhesins for AIDS therapy,” [cited by applicant]
Challita-Eid et al., “Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models,” [cited by applicant]
Chauvin et al., “TIGIT in cancer immunotherapy,” [cited by applicant]
Chothia et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” [cited by applicant]
Co et al., “Chimeric and Humanized Antibodies With Specificity for the CD33 Antigen [cited by applicant]
Co et al., “Humanized antibodies for antiviral therapy,” [cited by applicant]
Database Caplus Chemical Abstracts Service, Columbus, Ohio, US; Database Accession No. 2017:1888322,Abstract of WO 2017202704, F. Hoffmann-La Roche AG, 2017. (19 pages). [cited by applicant]
DeRycke et al., “Nectin 4 Overexpression in Ovarian Cancer Tissues and Serum: Potential Role as a Serum Biomarker,” [cited by applicant]
Evans, “Synthesis of Radiolabelled Compounds,” [cited by applicant]
Extended European Search Report, dated Mar. 4, 2020, for European Application No. 18767012.0. (4 pages). [cited by applicant]
Extended European Search Report, dated Sep. 4, 2020, for European Application No. 18744145.6. (9 pages). [cited by applicant]
Fabre-Lafay et al., “Nectin-4 is a new histological and serological tumor associated marker for breast cancer,” [cited by applicant]
Fedorak et al., “A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis,” [cited by applicant]
Gadd et al., “Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity,” [cited by applicant]
Guiducci et al., “RNA recognition by human TLR8 can lead to autoimmune inflammation,” [cited by applicant]
Hochhaus et al., “A Selective HPLC/RIA for Dexamethasone and its Prodrug Dexamethasone-21-sulphobenzoate Sodium in Biological Fluids,” [cited by applicant]
Honegger et al., “Yet Another Numbering Scheme for Immunoglobulin Variable Domains: An Automatic Modeling and Analysis Tool,” [cited by applicant]
International Search Report and Written Opinion, dated Jul. 3, 2018, for International Patent Application No. PCT/US2018/022510. (18 pages). [cited by applicant]
International Search Report and Written Opinion, dated Jul. 30, 2018, for International Patent Application No. PCT/US2018/015607. (16 pages). [cited by applicant]
International Search Report, dated Aug. 3, 2017, for International Patent Application No. PCT/CN2017/083031. (7 pages). [cited by applicant]
Jain et al., “Current ADC Linker Chemistry,” [cited by applicant]
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” [cited by applicant]
Kabalka et al., “The Synthesis of Radiolabeled Compounds Via Organometallic Intermediates,” [cited by applicant]
Kim et al., “High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice,” [cited by applicant]
Larsen et al., “Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamidines, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives,” [cited by applicant]
Larsen et al., “Prodrug forms for the sulfonamide group. II. Water-soluble amino acid derivatives of N-methylsulfonamides as possible prodrugs,” [cited by applicant]
Lattanzio et al., “Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer,” [cited by applicant]
Leone et al., “Targeting adenosine for cancer immunotherapy,” [cited by applicant]
Ma et al., “Expression and clinical significance of Nectin-4 in hepatocellular carcinoma,” [cited by applicant]
Mark III et al., “Derivation of Therapeutically Active Humanized and Veneered Anti-CD18 Antibodies,” in Metcalf et al. (eds.), [cited by applicant]
McLeod et al., “A Glucocorticoid Prodrug Facilitates Normal Mucosal Function in Rat Colitis Without Adrenal Suppression,” [cited by applicant]
Metz et al., “SBT6290, a Systemically Administered Nectin-4-Directed TLR8 Immunotac (TM) Therapeutic, is a Potent Human Myeloid Cell Agonist for the Treatment of Nectin-4- Expressing Tumors,” [cited by applicant]
Moyes et al., “Abstract 3271: A systemically administered, conditionally active TLR8 agonist for the treatment of HER2-expressing tumors,” Cancer Research, Proceedings of the American Association for Cancer Research Ann… [cited by applicant]
M-Rabet et al., “Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer,” [cited by applicant]
Mullins et al., “Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies,” [cited by applicant]
Nishii et al., “Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy” [cited by applicant]
Nishiwada et al., “Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer,” [cited by applicant]
Notice of Allowance, mailed Dec. 19, 2018, for U.S. Appl. No. 15/774,262, Coburn, “Benzazepine Compounds, Conjugates, and Uses Thereof,” 12 pages. [cited by applicant]
Notice of Allowance, mailed Jun. 14, 2019, for U.S. Appl. No. 15/973,506, Coburn, “Benzazepine Compounds, Conjugates, and Uses Thereof”, 7 pages. [cited by applicant]
Notice of Allowance, mailed May 13, 2019, for U.S. Appl. No. 16/274,132, Coburn, “Benzazepine Compounds, Conjugates, and Uses Thereof,” 9 pages. [cited by applicant]
Notice of Allowance, mailed May 13, 2019, for U.S. Appl. No. 16/274,130, Coburn, “Benzazepine Compounds, Conjugates, and Uses Thereof,” 9 pages. [cited by applicant]
Notice of Allowance, mailed Sep. 5, 2019, for U.S. Appl. No. 15/973,506, Coburn, “Benzazepine Compounds, Conjugates, and Uses Thereof”, 7 pages. [cited by applicant]
Office Action, mailed Dec. 6, 2018, for U.S. Appl. No. 15/973,506, Coburn, “Benzazepine Compounds, Conjugates, and Uses Thereof,” 12 pages. [cited by applicant]
Office Action, mailed Mar. 11, 2019, for U.S. Appl. No. 16/274,130, Coburn, “Benzazepine Compounds, Conjugates, and Uses Thereof,” 14 pages. [cited by applicant]
Office Action, mailed Mar. 11, 2019, for U.S. Appl. No. 16/274,132, Coburn, “Benzazepine Compounds, Conjugates, and Uses Thereof,” 15 pages. [cited by applicant]
Queen et al., “A humanized antibody that binds to the interleukin 2 receptor,” [cited by applicant]
Reymond et al., “Nectin4/PRR4, a New Afadin-associated Member of the Nectin Family That Trans-interacts with Nectin1/PRR1 through V Domain Interaction,” [cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy,” [cited by applicant]
Sato-Kaneko et al., “Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer,” [cited by applicant]
Scholten et al., “Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells,” [cited by applicant]
Schrama et al., “Antibody targeted drugs as cancer therapeutics,” [cited by applicant]
Silverback Therapeutics, “A Study of SBT6050 Alone and in Combination with Pembrolizumab in Patients with Advanced HER2 Expressing Solid Tumors” URL: https://clinicaltrials.gov/ct2/show/record/NCT04460456, download date… [cited by applicant]
Sinkula et al., “Rationale for Design of Biologically Reversible Drug Derivatives: Prodrugs,” [cited by applicant]
Tan et al., ““Superhumanized” Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD281,” [cited by applicant]
Tempest et al., “Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo,” [cited by applicant]
Verhoeyen et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity,” [cited by applicant]
Wang et al., “The Functional Effects of Physical Interactions among Toll-like Receptors 7, 8, and 9*,” [cited by applicant]
Warr et al., “The International ImMunoGeneTics Database IMGT,” [cited by applicant]
Wu, “Strategies for designing synthetic immune agonists,” [cited by applicant]
Zeindler et al., “Nectin-4 Expression Is an Independent Prognostic Biomarker and Associated With Better Survival in Triple-Negative Breast Cancer,” [cited by applicant]
Zhang et al., “High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer,” [cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” [cited by applicant]